Allergan is in the midst of acquiring Motus Therapeutics, a subsidiary of Rhythm Holding Company, after its relamorelin prescription achieved top line results in a phase 2b clinical trial.
Here's what you should know.
1. The prescription is used to treat gastroparesis in patients with type 1 and type 2 diabetes.
2. The trial evaluated the effects of relamorelin on key signs and symptoms of gastroparesis.
3. The trial was performed in a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of dosing requirements.
4. Relamorelin was found to be safe and well-tolerated. There were some dose-related adverse events associated with it including the worsening of glycemic control in some patients.
5. Allergan will pay $200 million to Rhythm Holdings at the deal's closing. Rhythm will also receive a contingent payment over the commercial sale of relamorelin.
More articles on GI/endoscopy:
Nonalcoholic fatty liver disease associated with $103B in annual medical costs: 3 study insights
https://www.beckersasc.com/gastroenterology-and-endoscopy/nonalcoholic-fatty-liver-disease-associated-with-103b-in-annual-medical-costs-3-study-insights.html
AGA launches patient education platform for IBD, pregnancy concerns: 3 notes
https://www.beckersasc.com/gastroenterology-and-endoscopy/aga-launches-patient-education-platform-for-ibd-pregnancy-concerns-3-notes.html
GI leader to know: Dr. R. David Shepard of Florida Medical Clinic
https://www.beckersasc.com/gastroenterology-and-endoscopy/gi-leader-to-know-dr-r-david-shepard-of-florida-medical-clinic.html